{"id":"NCT02546323","sponsor":"AstraZeneca","briefTitle":"A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-17","primaryCompletion":"2019-01-29","completion":"2019-01-29","firstPosted":"2015-09-10","resultsPosted":"2019-12-11","lastUpdate":"2019-12-11"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atherosclerosis"],"interventions":[{"type":"DRUG","name":"Rosuvastatin","otherNames":["Crestor"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rosuvastatin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.","primaryOutcome":{"measure":"Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period","timeFrame":"From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).","effectByArm":[{"arm":"Rosuvastatin 20 mg","deltaMin":0.0038,"sd":0.00312},{"arm":"Placebo","deltaMin":0.0142,"sd":0.00317}],"pValues":[{"comp":"OG000 vs OG001","p":"0.020"}]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":24,"countries":["China"]},"refs":{"pmids":["37565307","36017704","33176842"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3565C00003&amp;attachmentIdentifier=d2d6e1c4-2f54-4e4f-a110-cba7a24b341c&amp;fileName=D3565c00003_CSP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3565C00003&amp;attachmentIdentifier=6d21d378-0561-421c-88fb-99dc030ad2e8&amp;fileName=D3565c00003_SAP_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":272},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Blood glucose increased","Hypertension","Toothache"]}}